Financial Advocates Investment Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-13,133
Closed -$676K 805
2022
Q2
$676K Buy
13,133
+3,045
+30% +$158K 0.05% 331
2022
Q1
$743K Sell
10,088
-47,935
-83% -$4.27M 0.05% 358
2021
Q4
$3.52M Buy
58,023
+26,432
+84% +$4.54M 0.22% 112
2021
Q3
$5.08M Buy
31,591
+25,816
+447% +$5.69M 0.34% 66
2021
Q2
$1.62M Buy
+5,775
New +$1.06M 0.11% 233
2021
Q1
Sell
-1,293
Closed -$258K 782
2020
Q4
$726K Buy
+1,293
New +$137K 0.05% 370
2019
Q2
Sell
-1,000
Closed -$11K 481
2019
Q1
$11K Buy
+1,000
New +$31.6K ﹤0.01% 457

Other funds holding NVAX

Financial Advocates Investment Management's NVAX Position: Q3 2022 in Review

Financial Advocates Investment Management sold out of Novavax (NVAX) in Q3 2022, closing a stake of 13,133 shares — an estimated $676K sold.

Financial Advocates Investment Management first reported a position in NVAX in Q1 2019 and held it in 7 quarters. The position peaked at $5.08M in Q3 2021. 254 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

  • Financial Advocates Investment Management reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 13,133 Novavax shares in Q3 2022, an estimated $676K.
  • Financial Advocates Investment Management first reported a position in Novavax in Q1 2019 and held it in 7 quarters.
  • Financial Advocates Investment Management's Novavax position peaked at $5.08M in Q3 2021.
  • 254 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Financial Advocates Investment Management's 13F filing for Q3 2022, filed 14 Nov 2022.